NEW YORK – AstraZeneca and Daiichi Sankyo said on Tuesday that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorization to their antibody drug conjugate trastuzumab deruxtecan (Enhertu) as a monotherapy for previously-treated, metastatic, HER2-positive breast cancer patients.